- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 160726, 10 pages
Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II Signaling
1Institute of Liver Diseases, ShuGuang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
3Shanghai Key Laboratory of Traditional Chinese Clinic Medicine, Shanghai 201203, China
4E-Institute of TCM Internal Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China
Received 10 July 2012; Revised 30 September 2012; Accepted 10 October 2012
Academic Editor: Adair Roberto Soares Santos
Copyright © 2012 Shu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. Roskams, “Relationships among stellate cell activation, progenitor cells, and hepatic regeneration,” Clinics in Liver Disease, vol. 12, no. 4, pp. 853–860, 2008.
- R. K. Moreira, “Hepatic stellate cells and liver fibrosis,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 11, pp. 1728–1734, 2007.
- S. K. Das and D. M. Vasudevan, “Genesis of hepatic fibrosis and its biochemical markers,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 4, pp. 260–269, 2008.
- G. Paizis, R. E. Gilbert, M. E. Cooper et al., “Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis,” Journal of Hepatology, vol. 35, no. 3, pp. 376–385, 2001.
- J. R. Jonsson, A. D. Clouston, Y. Ando et al., “Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis,” Gastroenterology, vol. 121, no. 1, pp. 148–155, 2001.
- H. Yoshiji, S. Kuriyama, J. Yoshii et al., “Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats,” Hepatology, vol. 34, no. 4, pp. 745–750, 2001.
- R. Bataller, P. Ginès, J. M. Nicolás et al., “Angiotensin II induces contraction and proliferation of human hepatic stellate cells,” Gastroenterology, vol. 118, no. 6, pp. 1149–1156, 2000.
- R. Bataller, P. Sancho-Bru, P. Ginès et al., “Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II,” Gastroenterology, vol. 125, no. 1, pp. 117–125, 2003.
- G. Paizis, M. E. Cooper, J. M. Schembri, C. Tikellis, L. M. Burrell, and P. W. Angus, “Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver,” Gastroenterology, vol. 123, no. 5, pp. 1667–1676, 2002.
- R. Bataller, E. Gäbele, R. Schoonhoven et al., “Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 285, no. 3, pp. G642–G651, 2003.
- E. E. Powell, C. J. Edwards-Smith, J. L. Hay et al., “Host genetic factors influence disease progression in chronic hepatitis C,” Hepatology, vol. 31, no. 4, pp. 828–833, 2000.
- X. Li, Y. Meng, P. Wu, Z. Zhang, and X. Yang, “Angiotensin II and Aldosterone stimulating NF-κB and AP-1 activation in hepatic fibrosis of rat,” Regulatory Peptides, vol. 138, no. 1, pp. 15–25, 2007.
- L. Yang, R. Bataller, J. Dulyx et al., “Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice,” Journal of Hepatology, vol. 43, no. 2, pp. 317–323, 2005.
- X. N. Wang, Y. Y. Hu, C. H. Liu, P. Liu, and D. Y. Zhu, “Effects of salvianolic acid B on expressions of TGF-beta1 and its receptors in liver of rats with dimethylnitrosamine-induced hepatic fibrosis,” Zhong Xi Yi Jie He Xue Bao, vol. 3, no. 4, pp. 286–289, 2005.
- R. Bataller and D. A. Brenner, “Liver fibrosis,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005.
- R. P. Marshall, R. J. McAnulty, and G. J. Laurent, “Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 6, pp. 1999–2004, 2000.
- A. Douillette, A. Bibeau-Poirier, S. P. Gravel et al., “The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IκB kinase complex,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13275–13284, 2006.
- M. Ruiz-Ortega, O. Lorenzo, M. Rupérez, Y. Suzuki, and J. Egido, “Angiotensin II activates nuclear transcription factor-κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice,” Nephrology Dialysis Transplantation, vol. 16, supplement 1, pp. 27–33, 2001.
- H. Jin, N. Yamamoto, K. Uchida, S. Terai, and I. Sakaida, “Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet,” Biochemical and Biophysical Research Communications, vol. 364, no. 4, pp. 801–807, 2007.
- F. J. Yu, P. H. Dong, X. F. Fan, Z. Lin, Y. P. Chen, and J. Li, “Down-regulation of angiotensin II by shRNA reduces collagen synthesis in hepatic stellate cells,” International Journal of Molecular Medicine, vol. 25, no. 5, pp. 801–806, 2010.
- A. Hirose, M. Ono, T. Saibara et al., “Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis,” Hepatology, vol. 45, no. 6, pp. 1375–1381, 2007.
- Y. Nabeshima, S. Tazuma, K. Kanno et al., “Anti-fibrogenic function of angiotensin II type 2 receptor in induced liver fibrosis,” Biochemical and Biophysical Research Communications, vol. 346, no. 3, pp. 658–664, 2006.
- K. Kanno, S. Tazuma, and K. Chayama, “AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl4,” Biochemical and Biophysical Research Communications, vol. 308, no. 1, pp. 177–183, 2003.
- D. C. Rockey, “Current and future anti-fibrotic therapies for chronic liver disease,” Clinics in Liver Disease, vol. 12, no. 4, pp. 939–962, 2008.
- P. Liu, Y. Y. Hu, C. Liu et al., “Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B,” World Journal of Gastroenterology, vol. 11, no. 19, pp. 2892–2899, 2005.
- C. Liu, C. M. Jiang, C. H. Liu, P. Liu, and Y. Y. Hu, “Effect for Fuzhenghuayu decoction on vascular endothelial growth factor secretion in hepatic stellate cells,” Hepatobiliary and Pancreatic Diseases International, vol. 1, no. 2, pp. 207–210, 2002.
- C. Liu, P. Liu, C. H. Liu, X. Q. Zhu, and G. Ji, “Effects of Fuzhenghuayu decoction on collagen synthesis of cultured hepatic stellate cells, hepatocytes and fibroblasts in rats,” World Journal of Gastroenterology, vol. 4, no. 6, pp. 548–549, 1998.
- C. Liu, C. Jiang, C. Liu, P. Liu, and Y. Hu, “Intervention of Fuzhenghuayu decoction on autocrine activation of hepatic stellate cells,” Zhonghua Gan Zang Bing Za Zhi, vol. 9, no. 5, pp. 282–284, 2001.
- P. Liu, Y. Y. Hu, C. Liu et al., “Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B,” World Journal of Gastroenterology, vol. 8, no. 4, pp. 679–685, 2002.
- L. Wang, Y. Tao, S. Li, G. Chen, and C. Liu, “Effects of salvianolic acid B on lipid peroxidation and metalloproteinase-2 activity in fibrotic liver in rat,” Zhongguo Zhongyao Zazhi, vol. 35, no. 1, pp. 71–75, 2010.
- S. L. Friedman, D. C. Rockey, R. F. McGuire, J. J. Maher, J. K. Boyles, and G. Yamasaki, “Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture,” Hepatology, vol. 15, no. 2, pp. 234–243, 1992.
- M. A. Sohail, A. Z. Hashmi, W. Hakim et al., “Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition,” Hepatology, vol. 49, no. 1, pp. 185–194, 2009.
- M. Moreno, L. N. Ramalho, P. Sancho-Bru et al., “Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 296, no. 2, pp. G147–G156, 2009.
- S. Y. Kim, B. H. Cho, and U. H. Kim, “CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation,” Journal of Biological Chemistry, vol. 285, no. 1, pp. 576–582, 2010.
- L. Wang, C. liu, Y. Chen, Y. Tao, T. Zhou, and G. A. Cheng, “Modified methed to create rat model of hepatic fibrosis with dimethylnitrosamine and its pathological characteristics,” Acta Laroratorium Animalis Scientia Sinca, vol. 17, no. 2, pp. 90–94, 2007.
- S. Vogel, R. Piantedosi, J. Frank et al., “An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro,” Journal of Lipid Research, vol. 41, no. 6, pp. 882–893, 2000.
- J. Liu, H. Gong, Z. T. Zhang, and Y. Wang, “Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells,” Chinese Medical Journal, vol. 121, no. 2, pp. 161–165, 2008.
- H. S. Wei, H. M. Lu, D. G. Li et al., “The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCL4,” World Journal of Gastroenterology, vol. 6, no. 6, pp. 824–828, 2000.
- P. Moreno-Alvarez, M. Sosa-Garrocho, M. A. Briones-Orta et al., “Angiotensin II increases mRNA levels of all TGF-β isoforms in quiescent and activated rat hepatic stellate cells,” Cell Biology International, vol. 34, no. 10, pp. 969–978, 2010.
- Z. Lv, Y. Song, D. Xue, W. Zhang, Y. Cheng, and L. Xu, “Effect of Salvianolic-acid B on inhibiting MAPK signaling induced by transforming growth factor-β1 in activated rat hepatic stellate cells,” Journal of Ethnopharmacology, vol. 132, no. 2, pp. 384–392, 2010.
- H. J. Schaeffer and M. J. Weber, “Mitogen-activated protein kinases: specific messages from ubiquitous messengers,” Molecular and Cellular Biology, vol. 19, no. 4, pp. 2435–2444, 1999.
- G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002.
- T. Wada and J. M. Penninger, “Mitogen-activated protein kinases in apoptosis regulation,” Oncogene, vol. 23, no. 16, pp. 2838–2849, 2004.
- F. Chang, L. S. Steelman, J. T. Lee et al., “Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention,” Leukemia, vol. 17, no. 7, pp. 1263–1293, 2003.
- P. K. Vogt, “Jun, the oncoprotein,” Oncogene, vol. 20, no. 19, pp. 2365–2377, 2001.